DK3157527T3 - Ezh2-hæmmere til lymfombehandling - Google Patents
Ezh2-hæmmere til lymfombehandling Download PDFInfo
- Publication number
- DK3157527T3 DK3157527T3 DK15809540.6T DK15809540T DK3157527T3 DK 3157527 T3 DK3157527 T3 DK 3157527T3 DK 15809540 T DK15809540 T DK 15809540T DK 3157527 T3 DK3157527 T3 DK 3157527T3
- Authority
- DK
- Denmark
- Prior art keywords
- ezh2 inhibitors
- lymphoma treatment
- lymphoma
- treatment
- ezh2
- Prior art date
Links
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 title 1
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 title 1
- 206010025323 Lymphomas Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462013522P | 2014-06-17 | 2014-06-17 | |
US201462036265P | 2014-08-12 | 2014-08-12 | |
PCT/US2015/036310 WO2015195848A1 (en) | 2014-06-17 | 2015-06-17 | Ezh2 inhibitors for treating lymphoma |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3157527T3 true DK3157527T3 (da) | 2023-07-03 |
Family
ID=54936086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15809540.6T DK3157527T3 (da) | 2014-06-17 | 2015-06-17 | Ezh2-hæmmere til lymfombehandling |
Country Status (21)
Country | Link |
---|---|
US (5) | US10166238B2 (da) |
EP (2) | EP4252851A3 (da) |
JP (1) | JP6779793B2 (da) |
KR (2) | KR102497728B1 (da) |
CN (2) | CN113289022A (da) |
AU (3) | AU2015277139A1 (da) |
BR (1) | BR112016029492A2 (da) |
CA (1) | CA2952074C (da) |
DK (1) | DK3157527T3 (da) |
EA (1) | EA038337B1 (da) |
ES (1) | ES2948442T3 (da) |
FI (1) | FI3157527T3 (da) |
HU (1) | HUE062158T2 (da) |
IL (3) | IL285201B2 (da) |
LT (1) | LT3157527T (da) |
MX (2) | MX2021007651A (da) |
PL (1) | PL3157527T3 (da) |
PT (1) | PT3157527T (da) |
SG (2) | SG11201610273VA (da) |
SI (1) | SI3157527T1 (da) |
WO (1) | WO2015195848A1 (da) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
IL282741B2 (en) | 2013-12-06 | 2024-01-01 | Epizyme Inc | Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer |
MX2021007651A (es) * | 2014-06-17 | 2021-08-11 | Epizyme Inc | Inhibidores de ezh2 para tratar linfomas. |
CA2963149A1 (en) | 2014-10-16 | 2016-04-21 | Epizyme, Inc. | Method for treating cancer |
AU2015350108B2 (en) * | 2014-11-17 | 2021-04-08 | Eisai R&D Management Co., Ltd. | Method for treating cancer |
TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ezh2抑制劑 |
EA201792304A1 (ru) | 2015-04-20 | 2018-03-30 | Эпизайм, Инк. | Комбинированная терапия для лечения рака |
CN107635965A (zh) | 2015-06-10 | 2018-01-26 | Epizyme股份有限公司 | 用于治疗淋巴瘤的ezh2抑制剂 |
US10493076B2 (en) | 2015-08-24 | 2019-12-03 | Epizyme, Inc. | Method for treating cancer |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
AU2017211331A1 (en) * | 2016-01-29 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2017210395A1 (en) | 2016-06-01 | 2017-12-07 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
WO2017218953A1 (en) | 2016-06-17 | 2017-12-21 | Epizyme, Inc. | Ezh2 inhibitors for treating cancer |
CN110475557B (zh) * | 2017-01-20 | 2023-06-20 | 星座制药公司 | 固体分散体 |
WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
JP2020522687A (ja) | 2017-06-02 | 2020-07-30 | エピザイム,インコーポレイティド | 癌を処置するためのezh2阻害剤の使用 |
US20210161883A1 (en) * | 2017-07-10 | 2021-06-03 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibitor-induced gene expression |
JP7399079B2 (ja) | 2017-09-05 | 2023-12-15 | エピザイム,インコーポレイティド | 癌を処置するための併用療法 |
CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
EP2614369B1 (en) | 2010-09-10 | 2016-02-03 | Epizyme, Inc. | Method for determining the suitability of inhibitors of human ezh2 in treatment |
EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
JP2014534178A (ja) | 2011-09-30 | 2014-12-18 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC | 癌の処置方法 |
EP3536314A1 (en) * | 2012-03-12 | 2019-09-11 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
BR112014025508B1 (pt) | 2012-04-13 | 2020-11-17 | Eisai R&D Management Co., Ltd. | forma de sal de um inibidor de histona metiltransferase ezh2 humana |
IL289300B2 (en) | 2012-04-13 | 2024-05-01 | Epizyme Inc | Combined treatment for cancer |
WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
HUE046790T2 (hu) | 2012-10-15 | 2020-03-30 | Epizyme Inc | A rák kezelésének módszerei |
MY180311A (en) | 2012-10-15 | 2020-11-28 | Epizyme Inc | Substituted benzene compounds |
US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
AU2013337717B2 (en) * | 2012-11-01 | 2018-10-25 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using PI3 kinase isoform modulators |
US20150283142A1 (en) | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
EP2934531A4 (en) | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
EP2935264B1 (en) | 2012-12-21 | 2017-10-18 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
WO2014172044A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5 |
RU2019134551A (ru) * | 2013-05-30 | 2019-11-22 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
EP3022195A2 (en) | 2013-07-19 | 2016-05-25 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
EP3055422B1 (en) | 2013-10-09 | 2018-11-14 | Roche Diagnostics GmbH | Methods and compositions for detecting a mutation in the human ezh2 gene |
EP4324525A3 (en) | 2013-10-16 | 2024-07-17 | Epizyme, Inc. | Hydrochloride salt form for ezh2 inhibition |
JP2016533364A (ja) | 2013-10-18 | 2016-10-27 | エピザイム,インコーポレイティド | 癌を処置する方法 |
IL282741B2 (en) | 2013-12-06 | 2024-01-01 | Epizyme Inc | Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer |
MX2021007651A (es) | 2014-06-17 | 2021-08-11 | Epizyme Inc | Inhibidores de ezh2 para tratar linfomas. |
CA2966336A1 (en) | 2014-11-06 | 2016-05-12 | Dana-Farber Cancer Institute, Inc. | Use of compositions modulating chromatin structure for graft versus host disease (gvhd) |
AU2015350108B2 (en) | 2014-11-17 | 2021-04-08 | Eisai R&D Management Co., Ltd. | Method for treating cancer |
JP6544507B2 (ja) | 2015-02-09 | 2019-07-17 | 日本精機株式会社 | ヘッドアップディスプレイ装置 |
CN107635965A (zh) | 2015-06-10 | 2018-01-26 | Epizyme股份有限公司 | 用于治疗淋巴瘤的ezh2抑制剂 |
KR20170095656A (ko) | 2016-02-15 | 2017-08-23 | 동부대우전자 주식회사 | 방열구조를 갖는 세탁기 |
-
2015
- 2015-06-17 MX MX2021007651A patent/MX2021007651A/es unknown
- 2015-06-17 WO PCT/US2015/036310 patent/WO2015195848A1/en active Application Filing
- 2015-06-17 EA EA201692285A patent/EA038337B1/ru unknown
- 2015-06-17 CA CA2952074A patent/CA2952074C/en active Active
- 2015-06-17 PT PT158095406T patent/PT3157527T/pt unknown
- 2015-06-17 CN CN202110532717.0A patent/CN113289022A/zh active Pending
- 2015-06-17 IL IL285201A patent/IL285201B2/en unknown
- 2015-06-17 SG SG11201610273VA patent/SG11201610273VA/en unknown
- 2015-06-17 IL IL309539A patent/IL309539A/en unknown
- 2015-06-17 MX MX2016016744A patent/MX2016016744A/es unknown
- 2015-06-17 KR KR1020177000760A patent/KR102497728B1/ko active IP Right Grant
- 2015-06-17 ES ES15809540T patent/ES2948442T3/es active Active
- 2015-06-17 BR BR112016029492A patent/BR112016029492A2/pt not_active Application Discontinuation
- 2015-06-17 SG SG10201811128RA patent/SG10201811128RA/en unknown
- 2015-06-17 CN CN201580036258.XA patent/CN106999498B/zh active Active
- 2015-06-17 LT LTEPPCT/US2015/036310T patent/LT3157527T/lt unknown
- 2015-06-17 SI SI201531951T patent/SI3157527T1/sl unknown
- 2015-06-17 US US15/319,535 patent/US10166238B2/en active Active
- 2015-06-17 DK DK15809540.6T patent/DK3157527T3/da active
- 2015-06-17 FI FIEP15809540.6T patent/FI3157527T3/fi active
- 2015-06-17 HU HUE15809540A patent/HUE062158T2/hu unknown
- 2015-06-17 PL PL15809540.6T patent/PL3157527T3/pl unknown
- 2015-06-17 JP JP2016573564A patent/JP6779793B2/ja active Active
- 2015-06-17 KR KR1020237004113A patent/KR20230031963A/ko not_active Application Discontinuation
- 2015-06-17 EP EP23174369.1A patent/EP4252851A3/en active Pending
- 2015-06-17 AU AU2015277139A patent/AU2015277139A1/en not_active Abandoned
- 2015-06-17 EP EP15809540.6A patent/EP3157527B1/en active Active
-
2016
- 2016-12-07 IL IL249438A patent/IL249438A0/en unknown
-
2018
- 2018-11-06 US US16/181,747 patent/US20190175604A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,835 patent/US20200022987A1/en not_active Abandoned
-
2020
- 2020-03-04 US US16/808,513 patent/US11642347B2/en active Active
- 2020-09-28 AU AU2020244382A patent/AU2020244382B2/en active Active
-
2022
- 2022-11-03 AU AU2022263523A patent/AU2022263523A1/en active Pending
-
2023
- 2023-03-23 US US18/188,716 patent/US20240058348A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285201A (en) | EZH2 inhibitors for the treatment of lymphoma | |
IL287113A (en) | smyd inhibitors | |
IL256056A (en) | ezh2 inhibitors for the treatment of lymphoma | |
IL246902B (en) | Dihydropyrrolopyridine ror–gamma inhibitors | |
DK3389778T3 (da) | Indretning til fotodynamisk behandling | |
HUE042335T2 (hu) | ROR-gamma dihidropirrolopiridin inhibitorai | |
BR112017004334A2 (pt) | inibidores de desmetilase específica de lisina-1. | |
DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
BR112016030697A2 (pt) | inibidores da desmetilase-1 específica da lisina | |
DK3204386T3 (da) | Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed | |
IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
DK3191487T3 (da) | Spirocykliske cathepsin-c-inhibitorer | |
BR112017000042A2 (pt) | inibidores de desmetilase-1 lisina-específica | |
CU20160125A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3341379T3 (da) | EZH2-hæmmere | |
DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
EP3191185A4 (en) | Device for targeted treatment of dermastoses | |
DK3186242T3 (da) | Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere | |
DK3114120T3 (da) | Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere | |
HUE049600T2 (hu) | GLS1 inhibitorok betegségek kezelésére | |
DK3122308T3 (da) | Indretning til behandling af smerte | |
DK3237407T3 (da) | 3,5-diaminopyrazolkinasehæmmere | |
DK3294682T3 (da) | Sammensætning til overfladebehandling | |
DK3164195T3 (da) | Glutaminaseinhibitorterapi |